Given that this pathway is mutated in the majority of GBM and that the hyper-activated AKT helps glioma cells grow uncontrollably, evade apoptosis, and enhance tumor invasion, targeting this pathway has been an attractive therapeutic strategy for glioma (McDowell et al., 2011; Zhang et al., 2021). The gene discussed is AKT1; the disease is central nervous system cancer.